Latest news with #interstitiallungdisease
Medscape
06-08-2025
- Health
- Medscape
Abatacept May Give Better Outcomes Than Rituximab in RA-ILD
TOPLINE: Among patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD), abatacept was linked to better outcomes, including a lower risk for mortality, hospitalization, or mechanical ventilation, than rituximab. METHODOLOGY: Researchers conducted a retrospective cohort study comparing the effectiveness and safety of abatacept vs rituximab for RA-ILD using an emulated target trial design, with data obtained from the TriNetX US Collaborative Network database. Adults diagnosed with RA-ILD who initiated abatacept treatment were propensity matched with those who initiated rituximab (n = 1615 in each treatment group) between January 2007 and June 2024. The primary outcome was all-cause mortality, and secondary outcomes included hospitalization, mechanical ventilation, medical utilization, and infection-related complications such as bacteremia and pneumonia. TAKEAWAY: Treatment with abatacept was associated with lower risk for all-cause mortality than treatment with rituximab (hazard ratio [HR], 0.689; 95% CI, 0.581-0.818) during the 5-year follow-up period. Additionally, abatacept treatment was associated with reduced risks for hospitalization (HR, 0.882; 95% CI, 0.776-0.977) and mechanical ventilation (HR, 0.698; 95% CI, 0.521-0.934). Patients receiving abatacept had a lower incidence of pneumonia than those receiving rituximab (HR, 0.858; 95% CI, 0.754-0.977); however, the risk for bacteremia remained comparable between the groups. Abatacept users demonstrated significantly reduced risks for cyclophosphamide use (HR, 0.162; 95% CI, 0.090-0.291) and immunoglobulin use (HR, 0.232; 95% CI, 0.157-0.343). IN PRACTICE: 'This large, real-world target-trial emulation strengthens the evidence that abatacept may offer a more favorable outcome than rituximab in RA-ILD, with consistently lower risks of all-cause mortality across the subgroup and sensitivity analyses. By providing the first head-to-head comparison of these two biologics, the study provides a critical evidence gap in RA-ILD management,' the authors wrote. SOURCE: The study was led by Po-Cheng Shih, MD, Chung Shan Medical University, Taichung, Taiwan. It was published online on July 22, 2025, in Arthritis & Rheumatology. LIMITATIONS: Despite extensive matching, residual confounding by indication and unmeasured factors (eg, detailed smoking history, RA activity scores, and imaging-based ILD severity) may have existed. ILD diagnoses relied on diagnostic codes without direct radiologic or full pulmonary function confirmation, which may have led to misclassification. As this was a retrospective observational US-based study, causality could not be definitively established, and the findings may not be generalizable to other settings internationally. DISCLOSURES: No funding was received for this study. The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
31-07-2025
- Business
- Yahoo
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., July 31, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2025. To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at An archived replay of the webcast will also be available for 30 days on the Company's website following the event. About Trevi Therapeutics, Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Investor Contact Jonathan Carlson Trevi Therapeutics, Inc. (203) 654 3286 carlsonj@ Media Contact Rosalia Scampoli 914-815-1465 rscampoli@ View original content to download multimedia: SOURCE Trevi Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
